Post Reply
4981-5000 of 10899
ho sai liao,,,,,,,,,,,,,,,,lai liao,,,,,,,,,,,,,,,,,,,,,,,,,,,50cts tp,,,,,,,,,,,,,,,,,,,break up soon
ho sai liao,,,,,,,,,,,,,,,,must buy more signal,,,,,,,,,,,,,,,yesteerday buy 385cts,,,,,,,,,,,,,,,,38cts not done,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hope down can buy,,,,,,,,,,,,,,,,,,,hight can sell,,,,,,,,,,,,,,,,,,,,,tis one die die must buy,,,,,,,,,,,,,,,,,,,,,,,,,,,,i think 38cts very hard to get now,,,,,,,,,,,,,,,,,buy stll try,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,try,,,,,,,,,,,,,,,,,,,i dont mind,,,,,,,,,,,,,bec tis baby is my main flag ship..................................after sell all sar cheers
Barring any unforseen negative circumstances, it should catch up pretty soon, the gap is getting narrower .... 50ma at 0.38 and 200ma at 0.405 ....
Above not an inducement to trade. Cheers.
novena_33 ( Date: 08-Apr-2009 08:35) Posted:
|
more fund for me to loop it ,,,,,,,,,,,,,,,,,,,,,wait for me,,,,,,,,,,,,,,,,,,im confident the akan datang result,,,,,,share price,,,,,,,,,,,,,,,,,,,,,,,,,,and may be target of big fish,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tp 50cts,,,,,,,,,,,,,,,,,,,,,,even 60cts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,or double if big fish wanna take all,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cheers
Base on TA .....50 ma cut 200 ma is a golden cross.....hopefully it can cut up.....
Chart seems to be forming a symmetrical triangle... thus, it will either break out and trend up or down ...
Looking at the current trending, i'm betting that BIG will go up .... this pull back is not strong as the volume is not significant..... the next few days will be very exiciting ...
One important thing to note is that BIG trading price had FINALLY touches the Moving Average pricing based on 200 days. From wat i understand is that if a counter is trading above the 200 days moving avarage price, it is consider on the bull side ... and this is normally how they use to see if the STI or DOW is in the bull or bear region ....
So in my opinion with the recent happening at the price movement... BIG should be waiting for a major run-up based on the following:
1) Chart shows a symmetrical triangle for a major break out - recent price movement is very encouraging especially the last 3 days run up with significant volume....
2) Today pull back - Not significant as volume is not high (may be some profit taking from the last few days run up)... Next few days will be exicitng ....
3) BIG trading price finally met the 200MA pricing (infact it had cross over the last few days). The 200 days moving average price is around 0.405 ..... Thus, any break out from here will be definitely bullish in BIG's perspective.
4) BIG had already end its FY09. And it is now in the very anticpated FY10....
5) BIG full year FY09 results will be out soon .. in 3-4 weeks time .... The FY09 results is important but i personally think that many serious investor(fund house) is MORE CONCERN on what the CEO had for FY10 rather than FY09 as this is already history ...... Share price always move ahead ... Thus, any price movement now is anticpating for FY10 stunning performance ......
My conclusion: limited downside but very high potential on high side ... so my bet is on BIG..... Anyway, if you look across SGX .... i dun think you can find any counter that is trending like BIG for the past few months ..... i think not many especially now ........
Cheers .... me too will still collect some more if BIG still pull back with no significant volume.
Above is my 2 cents worth of personal opinion and not an inducement to trade. Each to his own trading strategy.
Good Luck to ALL. Long weekend coming .....
i m here again,,,,,,,,,,,,still got potential,,,,,,,,,,,,50cts is my tp,,,,,,,,,may be 60cts,,,,,,,,,,too sad it back to 395cts,,,,,,,,,,,,,,,,,,im still holding,,,,,,,,,,,,,,,,,,,im going to buy more if pull back more,,,,,,,,,,,,,,,,,,,,,,,,,too bad i cant use cpf,,,,,,,,,,,,,,,,,,,,cheers
$40mil is non recurring but extraordinary-a one time thing but still gd...at least the P/L looks nicer
wow,,,,,,,,,,,40million profit,,,,,,,,,,,im going to raise tis baby to 60cts,,,,,,,,,,,,,,or even double it 1,00 stock,,,,,,,,,,so that the big fund can buy liao,,,,,,,,,,,,,,,,, cheers
BIG will turn around esp with extraordinary profit of US40mil from a licensee offset by non-recurring restructuring charges for the US and netherlands ops....loses from main business likely to lessen or even just went into the black even if to exclude the one time extraordinary gain...limited donwnside 25cts but upside now...shd accumulate
Maxximo ( Date: 26-Mar-2009 23:36) Posted:
|
bro..what's the tp?
laai liao
ppl just profit taking ,,,,,,,,,,,,,,,,,,,,,lai liao,,,,,,,,,,,,,,,bb is still there,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50cts tp
Tks 4 d good advice. Ought to be careful, as d up-down stock market may get u pant down, anytime, be it bad or good sentiments. Cheers.
knightbridge ( Date: 06-Apr-2009 10:49) Posted:
|
Uncle AK got to be careful.. You are quite negative earlier in jan. now market move almost 500pts .. Dont jump in too much at this moment
North Korean and Thai protest may start to haunt singapore stock market if not under control.. I am waiting to unload all my jan purchase,, hoping more investor can push up and i will sell out part by part
AK_Francis ( Date: 06-Apr-2009 09:26) Posted:
|
BIG is about to take flight on its H.S.
Target price $0..52 
CHEERS!!!!!!!!!!!!!!!!!!!!!!!!!!!
louis_leecs ( Date: 06-Apr-2009 10:08) Posted:
|
very ssoonn can see 50cts tp
very active 2day. seems good loh. tks for d support.
im come back again,,,,,,,,,,,,start with small,,,,,,,,,,slowly,,,,,,,,,,,patience,,,,,,,,,,,,,continious buy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tis baby,,,,,,,,,,,,,,,,,,cheeeeeeeeeeeeeeeeeers
Boston Scientific Stents Less Effective Than Rivals (Update2)
2009-03-30 20:34:55.201 GMT
(Adds closing share prices in the 10th paragraph.)
By Alex Nussbaum
March 30 (Bloomberg) -- Heart stents made by Boston
Scientific Corp., the world’s biggest seller of the artery-
clearing devices, were less effective in studies than those from
Abbott Laboratories, Johnson & Johnson and Medtronic Inc.
Taxus Liberte, Boston Scientific’s newest stent, required
more repeat procedures than products from Medtronic and J&J in a
South Korean study reported yesterday at the American College of
Cardiology meeting in Orlando, Florida. In a separate trial, two
Taxus models were linked with an 88 percent higher risk of
heart-related deaths than Abbott’s market-leading Xience stent.
Stent makers are competing for a $4 billion market. In
January, seven months after its U.S. debut, Xience had grabbed
28 percent of the market, Boston Scientific said in a call with
investors. Taxus, with 24 percent, was third behind the 25
percent recorded for a Xience copy, called Promus, that is
licensed from Abbott and sold by Boston Scientific.
Market leadership is “just a credit to Boston’s sales and
marketing prowess,” said Tim Fischell, the director of
cardiovascular research at Borgess Research Institute in
Kalamazoo, in an e-mail. Given the stent’s showing in past
trials, “it’s amazing that Taxus is used over J&J’s Cypher,”
which has just 14 percent of the market.
Boston Scientific, based in Natick, Massachusetts, last
year introduced both Taxus Liberte, an updated version of the
company’s existing drug-coated stent, and Promus, the Xience
copy it licenses from Abbott Park, Illinois-based Abbott. Stents
are tiny mesh devices that keep arteries from closing down after
they’ve been cleared with angioplasty.
Tough Weekend
The results for Xience and for Cypher, made by New
Brunswick, New Jersey-based J&J, are unlikely to change market
share, said Sidney Smith, a University of North Carolina
cardiologist, in a telephone interview. Xience, introduced in
July, is already the top-selling stent. Also, some doctors were
skeptical about Cypher’s surprisingly low rate of triggering
blood clots in the South Korean trial, called Zest, Smith said.
“This weekend’s session was tough on Boston Scientific,”
especially the “surprisingly negative” results for Taxus
Liberte in Zest, said Michael Weinstein, a J.P. Morgan Chase &
Co. analyst in New York, in a note to clients today.
Still, Xience’s continued popularity will likely pump up
Promus sales as well, “blunting the impact of any further
decline in Taxus’s share position,” Weinstein said.
Good for Medtronic
Medtronic, whose share of the stent market had fallen to 9
percent in January, may also see its slide arrested by the
positive results, said Rick Wise, a Leerink Swann & Co. analyst
in New York, in another note. The company said this morning that
it expected to start selling Endeavor in Japan in May, after
regulators there approved the device.
Medtronic rose 25 cents, less than 1 percent, to $29.03 in
composite New York Stock Exchange trading at 4:15 p.m. Boston
Scientific dropped 24 cents, or 2.9 percent, to $7.96. J&J
gained 18 cents to $53.01 and Abbott rose $1.29, or 2.8 percent,
to $47.89.
With all four company’s stents performing relatively
equally in past studies, the battle may come down to price, said
Smith, the cardiologist who is director of the University of
North Carolina’s Center for Cardiovascular Science and Medicine.
Drug-coated stents sell for $2,000 apiece, and the
manufacturers so far haven’t shown any willingness to compete on
cost, he said.
“The results we’re seeing in Zest and the other trials
don’t really argue for choosing one stent over another,” Smith
said. “In that setting, price is going to become a bigger
factor to consider.”
Cypher More Effective
The Zest researchers found Cypher more effective at keeping
arteries open, and at least as safe, as Medtronic’s Endeavor and
Taxus Liberte. The study, partly funded by Medtronic, found
Endeavor equally as effective as Taxus Liberte and safer.
Patients using Cypher needed a second procedure to open a
reclogged artery 1.4 percent of the time, compared with 4.9
percent for Endeavor and 7.6 percent for Boston Scientific’s
model, researchers said.
“There’s a significant difference in disfavor of
Endeavor” and for Cypher, said Stephan Windecker, a
cardiologist at the University of Bern in Switzerland.
The trial results demonstrate “not all drug-eluting
stents are the same,” said Christopher Allman, a J&J spokesman,
in an e-mail. “Only Cypher has shown sustained patient outcomes
now out to six years, which is another point of differentiation
among drug eluting stents.”
Fewer Clots
The study showed Endeavor to be “non-inferior” to Cypher
in terms of safety, while it had 29 percent fewer deaths, heart
attacks and repeat procedures than the better-selling Liberte,
said Joseph McGrath, a Medtronic spokesman, in an e-mail.
The trial found a much lower rate of clotting for Cypher and
higher rates of repeat procedures for Liberte than past studies,
so conclusions should be tempered by those past results, said
Donald Baim, Boston Scientific’s chief medical officer.
“This data doesn’t jibe with what we know with all the
other trials,” Baim said in an interview.
Boston Scientific has kept its grip on the market partly
due to its two offerings, Taxus Liberte and Promus, Baim said.
Each has a different drug coating and underlying architecture
that serve different types of patients, he said.
The second study, called Spirit 2, gave results for Xience
patients at three years, the longest review yet of the Abbott
stent’s performance.
Among 223 Xience users, the rate of deaths, heart attacks
and repeat procedures stayed steady at 6.4 percent from years
two to three, Abbott said in a statement.
Cardiac-Related Deaths
Among 73 Taxus users, the figure rose from 10.5 to 14.9
percent in the study, which Abbott funded. The rate of cardiac-
related deaths was 0.5 percent for Xience patients in the third
year, compared with 4.2 percent for Taxus.
“In the clinical outcomes that matter most, such as heart
attacks, repeat procedures at the target lesion or death, Xience
demonstrated a consistent reduction relative to Taxus out to
three years,” said lead investigator Patrick Serruys, a
cardiologist at Erasmus University in Rotterdam, in the
statement.
A quarter of the Taxus stents were Liberte models while the
rest were an older version, the statement said.
For Related News and Information:
Bloomberg Reports on Science Studies: NI SCIENCE BN <GO>
News about Heart Stents: NSE STENT <GO>
Medical Device Company Returns: S5HCEP <Index> MRR <GO>
Today’s most popular health-care stories: MNI HEA <GO>
Investment picks in health care: TNI HEA GREET BN <GO>
Health Care Company Earnings: TNI EARN HEA BN <GO>
--Editors: Angela Zimm, Donna Alvarado
To contact the reporter on this story:
Alex Nussbaum in New York +1-212-617-5406 or
anussbaum1@bloomberg.net.
To contact the editor responsible for this story:
Reg Gale at +1-212-617-2563 or
Rgale5@bloomberg.net
2009-03-30 20:34:55.201 GMT
(Adds closing share prices in the 10th paragraph.)
By Alex Nussbaum
March 30 (Bloomberg) -- Heart stents made by Boston
Scientific Corp., the world’s biggest seller of the artery-
clearing devices, were less effective in studies than those from
Abbott Laboratories, Johnson & Johnson and Medtronic Inc.
Taxus Liberte, Boston Scientific’s newest stent, required
more repeat procedures than products from Medtronic and J&J in a
South Korean study reported yesterday at the American College of
Cardiology meeting in Orlando, Florida. In a separate trial, two
Taxus models were linked with an 88 percent higher risk of
heart-related deaths than Abbott’s market-leading Xience stent.
Stent makers are competing for a $4 billion market. In
January, seven months after its U.S. debut, Xience had grabbed
28 percent of the market, Boston Scientific said in a call with
investors. Taxus, with 24 percent, was third behind the 25
percent recorded for a Xience copy, called Promus, that is
licensed from Abbott and sold by Boston Scientific.
Market leadership is “just a credit to Boston’s sales and
marketing prowess,” said Tim Fischell, the director of
cardiovascular research at Borgess Research Institute in
Kalamazoo, in an e-mail. Given the stent’s showing in past
trials, “it’s amazing that Taxus is used over J&J’s Cypher,”
which has just 14 percent of the market.
Boston Scientific, based in Natick, Massachusetts, last
year introduced both Taxus Liberte, an updated version of the
company’s existing drug-coated stent, and Promus, the Xience
copy it licenses from Abbott Park, Illinois-based Abbott. Stents
are tiny mesh devices that keep arteries from closing down after
they’ve been cleared with angioplasty.
Tough Weekend
The results for Xience and for Cypher, made by New
Brunswick, New Jersey-based J&J, are unlikely to change market
share, said Sidney Smith, a University of North Carolina
cardiologist, in a telephone interview. Xience, introduced in
July, is already the top-selling stent. Also, some doctors were
skeptical about Cypher’s surprisingly low rate of triggering
blood clots in the South Korean trial, called Zest, Smith said.
“This weekend’s session was tough on Boston Scientific,”
especially the “surprisingly negative” results for Taxus
Liberte in Zest, said Michael Weinstein, a J.P. Morgan Chase &
Co. analyst in New York, in a note to clients today.
Still, Xience’s continued popularity will likely pump up
Promus sales as well, “blunting the impact of any further
decline in Taxus’s share position,” Weinstein said.
Good for Medtronic
Medtronic, whose share of the stent market had fallen to 9
percent in January, may also see its slide arrested by the
positive results, said Rick Wise, a Leerink Swann & Co. analyst
in New York, in another note. The company said this morning that
it expected to start selling Endeavor in Japan in May, after
regulators there approved the device.
Medtronic rose 25 cents, less than 1 percent, to $29.03 in
composite New York Stock Exchange trading at 4:15 p.m. Boston
Scientific dropped 24 cents, or 2.9 percent, to $7.96. J&J
gained 18 cents to $53.01 and Abbott rose $1.29, or 2.8 percent,
to $47.89.
With all four company’s stents performing relatively
equally in past studies, the battle may come down to price, said
Smith, the cardiologist who is director of the University of
North Carolina’s Center for Cardiovascular Science and Medicine.
Drug-coated stents sell for $2,000 apiece, and the
manufacturers so far haven’t shown any willingness to compete on
cost, he said.
“The results we’re seeing in Zest and the other trials
don’t really argue for choosing one stent over another,” Smith
said. “In that setting, price is going to become a bigger
factor to consider.”
Cypher More Effective
The Zest researchers found Cypher more effective at keeping
arteries open, and at least as safe, as Medtronic’s Endeavor and
Taxus Liberte. The study, partly funded by Medtronic, found
Endeavor equally as effective as Taxus Liberte and safer.
Patients using Cypher needed a second procedure to open a
reclogged artery 1.4 percent of the time, compared with 4.9
percent for Endeavor and 7.6 percent for Boston Scientific’s
model, researchers said.
“There’s a significant difference in disfavor of
Endeavor” and for Cypher, said Stephan Windecker, a
cardiologist at the University of Bern in Switzerland.
The trial results demonstrate “not all drug-eluting
stents are the same,” said Christopher Allman, a J&J spokesman,
in an e-mail. “Only Cypher has shown sustained patient outcomes
now out to six years, which is another point of differentiation
among drug eluting stents.”
Fewer Clots
The study showed Endeavor to be “non-inferior” to Cypher
in terms of safety, while it had 29 percent fewer deaths, heart
attacks and repeat procedures than the better-selling Liberte,
said Joseph McGrath, a Medtronic spokesman, in an e-mail.
The trial found a much lower rate of clotting for Cypher and
higher rates of repeat procedures for Liberte than past studies,
so conclusions should be tempered by those past results, said
Donald Baim, Boston Scientific’s chief medical officer.
“This data doesn’t jibe with what we know with all the
other trials,” Baim said in an interview.
Boston Scientific has kept its grip on the market partly
due to its two offerings, Taxus Liberte and Promus, Baim said.
Each has a different drug coating and underlying architecture
that serve different types of patients, he said.
The second study, called Spirit 2, gave results for Xience
patients at three years, the longest review yet of the Abbott
stent’s performance.
Among 223 Xience users, the rate of deaths, heart attacks
and repeat procedures stayed steady at 6.4 percent from years
two to three, Abbott said in a statement.
Cardiac-Related Deaths
Among 73 Taxus users, the figure rose from 10.5 to 14.9
percent in the study, which Abbott funded. The rate of cardiac-
related deaths was 0.5 percent for Xience patients in the third
year, compared with 4.2 percent for Taxus.
“In the clinical outcomes that matter most, such as heart
attacks, repeat procedures at the target lesion or death, Xience
demonstrated a consistent reduction relative to Taxus out to
three years,” said lead investigator Patrick Serruys, a
cardiologist at Erasmus University in Rotterdam, in the
statement.
A quarter of the Taxus stents were Liberte models while the
rest were an older version, the statement said.
For Related News and Information:
Bloomberg Reports on Science Studies: NI SCIENCE BN <GO>
News about Heart Stents: NSE STENT <GO>
Medical Device Company Returns: S5HCEP <Index> MRR <GO>
Today’s most popular health-care stories: MNI HEA <GO>
Investment picks in health care: TNI HEA GREET BN <GO>
Health Care Company Earnings: TNI EARN HEA BN <GO>
--Editors: Angela Zimm, Donna Alvarado
To contact the reporter on this story:
Alex Nussbaum in New York +1-212-617-5406 or
anussbaum1@bloomberg.net.
To contact the editor responsible for this story:
Reg Gale at +1-212-617-2563 or
Rgale5@bloomberg.net